---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-25-000049"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2025-11-07T23:59:59+00:00"
generated_at: "2026-05-16T22:55:52.749558+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Halozyme prices $1.3B convertible notes offering; to repurchase ~$1.02B of existing 2027/2028 notes

## Summary
- Priced $650M of 0% convertible notes due 2031 and $650M of 0.875% notes due 2032; initial purchasers have 13-day option for additional $200M.
- Initial conversion price of ~$87.20/share, a 27.5% premium over the $68.39 closing price on Nov. 6, 2025.
- Net proceeds of ~$1.274B ($1.47B if option exercised); ~$1.019B to repurchase outstanding 0.25% 2027 and 1.00% 2028 notes.
- Entered into capped call transactions with cap price of $136.78/share to reduce potential dilution upon conversion.
- Expected to close offering on November 12, 2025; remainder of proceeds for general corporate purposes.

## SEC filing metadata
- accession: 0001159036-25-000049
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2025-11-07T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903625000049/0001159036-25-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903625000049/halo-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-25-000049
- JSON: https://secwatch.observer/filing/0001159036-25-000049.json
- Plain text: https://secwatch.observer/filing/0001159036-25-000049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.